𝛼SK or Searchbullish
RedHill Biopharma - Transforming into a commercial pharma company
SUMMARY
With two specialty GI products launched and a third one, Movantik, about to be acquired from AstraZeneca, RedHill is transforming into a fully integrated pharma company. RedHill is now promoting Aemcolo for travellers’ diarrhoea (since December 2019) and Talicia for H. pylori eradication (since March 2020). About to be in-licensed, Movantik is an established product for opioid-induced constipation and AstraZeneca reported 2019 sales of $96m in the US, so it is a significant addition to RedHill’s portfolio. We value RedHill at $638m or $18.1 per ADS (vs $575m previously).
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- RedHill Biopharma - Transforming into a commercial pharma company18 Mar 2020
x